Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brand-Generic "Pay-For-Delay" Settlements Jump 63% In FY 2010

This article was originally published in The Pink Sheet Daily

Executive Summary

As a proportion of total settlements reported to FTC, however, the ones involving compensation to the generic firm remained the same.

You may also be interested in...



FTC Rushes Patent Settlement Report In Push For Super Committee Action On "Pay-For-Delay"

The Federal Trade Commission rushed to press the data about the number of patent settlements between brand and generic companies in FY 2011 in an apparent effort to grab the attention of the Joint Select Committee on Deficit Reduction.

FTC Rushes Patent Settlement Report In Push For Super Committee Action On "Pay-For-Delay"

The Federal Trade Commission rushed to press the data about the number of patent settlements between brand and generic companies in FY 2011 in an apparent effort to grab the attention of the Joint Select Committee on Deficit Reduction.

Authorized Generics Do Not Deter Patent Challenges, FTC Says, But May Be Used To Delay Competition

Authorized generics modestly reduce drug prices during the first 180 days of generic competition and substantially undercut the revenues of competing generic firms, according to the Federal Trade Commission.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072302

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel